Search

Your search keyword '"Lebray, Pascal"' showing total 332 results
Start Over Author "Lebray, Pascal"
332 results on '"Lebray, Pascal"'

1. Standardized immunosuppressive protocol to prevent rejection under immunotherapy for post liver transplantation HCC recurrence: A French center's experience

Author

Arcile, Gauthier, Bijot, Mathilde Aissaoui Jean Charles, Boughdad, Sarah, Bouzbib, Charlotte, Brisson, Hélène, Bonvallot, Harold, Charlotte, Frédéric, Decouen, Audrey, Delmotte, Pierre-Romain, Gallet, Jérémy, Gasperment, Maxime, Goumard, Claire, Halter, Sébastien, Jeune, Florence, Lebray, Pascal, Lim, Chétana, Lucidarme, Olivier, Maksud, Philippe, Mallet, Maxime, Masse, Anne-Lyse, Mazzola, Alessandra, Meyblum, Louis, Monsel, Antoine, Mouri, Sarah, Oré, Marie-Virginie, Perdigao, Fabiano, Renaud, Florence, Rousseau, Géraldine, Roux, Charles, Rudler, Marika, Savier, Eric, Simon, Jean Marc, Sibon, Alexandre, Spitzer, Eleonore, Sultanik, Philippe, Varin, Eloi, Vezinet, Corinne, Wagner, Mathilde, Giudicelli, Héloïse, Conti, Filomena, Scatton, Olivier, Thabut, Dominique, and Allaire, Manon

Published
2025
Full Text
View/download PDF

5. Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

Author

Téllez, Luis, Rincón, Diego, Payancé, Audrey, Jaillais, Anaïs, Lebray, Pascal, Rodríguez de Santiago, Enrique, Clemente, Ana, Paradis, Valerie, Lefort, Bruno, Garrido-Lestache, Elvira, Prieto, Raquel, Iserin, Laurence, Tallegas, Matthias, Garrido, Elena, Torres, María, Muriel, Alfonso, Perna, Cristian, del Cerro, María Jesús, d'Alteroche, Louis, Rautou, Pierre-Emmanuel, Bañares, Rafael, and Albillos, Agustín

Published
2024
Full Text
View/download PDF

6. HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation

Author

Coilly, Audrey, Sebagh, Mylène, Fougerou-Leurent, Claire, Pageaux, Georges-Philippe, Leroy, Vincent, Radenne, Sylvie, Silvain, Christine, Lebray, Pascal, Houssel-Debry, Pauline, Cagnot, Carole, Rossignol, Emilie, Danjou, Hélène, Veislinger, Aurélie, Samuel, Didier, Duclos-Vallée, Jean-Charles, and Dumortier, Jérôme

Published
2022
Full Text
View/download PDF

11. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients

Author

Altieri, Mario, Sérée, Olivier, Lobbedez, Thierry, Segol, Philippe, Abergel, Armand, Blaizot, Xavier, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Chazouillères, Olivier, Debette-Gratien, Maryline, Dharancy, Sébastien, Durand, François, Duvoux, Christophe, Francoz, Claire, Gugenheim, Jean, Hardwigsen, Jean, Houssel-Debry, Pauline, Kamar, Nassim, Latournerie, Marianne, Lebray, Pascal, Leroy, Vincent, Neau-Cransac, Martine, Pageaux, Georges-Philippe, Radenne, Sylvie, Salamé, Ephrem, Saliba, Faouzi, Samuel, Didier, Vanlemmens, Claire, Besch, Camille, Launoy, Guy, and Dumortier, Jérôme

Published
2021
Full Text
View/download PDF

18. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study

Author

Coilly, Audrey, Fougerou-Leurent, Claire, de Ledinghen, Victor, Houssel-Debry, Pauline, Duvoux, Christophe, Di Martino, Vincent, Radenne, Sylvie, Kamar, Nassim, D’Alteroche, Louis, Leroy, Vincent, Canva, Valérie, Lebray, Pascal, Moreno, Christophe, Dumortier, Jérôme, Silvain, Christine, Besch, Camille, Perre, Philippe, Botta-Fridlund, Danielle, Anty, Rodolphe, Francoz, Claire, Abergel, Armando, Debette-Gratien, Maryline, Conti, Filomena, Habersetzer, François, Rohel, Alexandra, Rossignol, Emilie, Danjou, Hélène, Roque-Afonso, Anne-Marie, Samuel, Didier, Duclos-Vallée, Jean-Charles, and Pageaux, Georges-Philippe

Published
2016
Full Text
View/download PDF

19. Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation

Author

Cortesi, Paolo Angelo, Viganò, Raffaella, Conti, Sara, Lenci, Ilaria, Volpes, Riccardo, Martini, Silvia, Angelico, Mario, Fung, James, Buti, Maria, Coilly, Audrey, Durand, Francois, Fondevila, Constantino, Lebray, Pascal, Nevens, Frederik, Polak, Wojciech G., Rizzetto, Mario, Zoulim, Fabien, Perricone, Giovanni, Berenguer, Marina, Mantovani, Lorenzo Giovanni, Duvoux, Christophe, Belli, Luca Saverio, Cortesi, Paolo Angelo, Viganò, Raffaella, Conti, Sara, Lenci, Ilaria, Volpes, Riccardo, Martini, Silvia, Angelico, Mario, Fung, James, Buti, Maria, Coilly, Audrey, Durand, Francois, Fondevila, Constantino, Lebray, Pascal, Nevens, Frederik, Polak, Wojciech G., Rizzetto, Mario, Zoulim, Fabien, Perricone, Giovanni, Berenguer, Marina, Mantovani, Lorenzo Giovanni, Duvoux, Christophe, and Belli, Luca Saverio

Abstract

The European Liver and Intestine Transplant Association, ELITA, promoted a Consensus Conference involving 20 experts across the world which generated updated guidelines on HBV prophylaxis in liver transplant candidates and recipients. This study explores the economic impact associated with the implementation of the new ELITA guidelines. To this aim, a condition-specific cohort simulation model has been developed to compare new and historical prophylaxis, including only pharmaceutical cost and using the European perspective. The target population simulated in the model included both prevalent and incident cases, and consisted of 6,133 patients after the first year, that increased to 7,442 and 8,743 patents after 5 and 10 years from its implementation. The ELITA protocols allowed a cost saving of around € 235.65 million after 5 years and € 540.73 million after 10 years; which was mainly due to early HIBG withdrawal either after the first 4 weeks or after the first year post Liver Transplantation (LT) depending on the virological risk at transplantation. Results were confirmed by sensitivity analyses. The money saved by the implementation of the ELITA guidelines would allow healthcare decision makers and budget holders to understand where costs could be reduced and resources re-allocated to different needs.

Published
2023

20. Utility of a Score-Based Approach to Liver Assessment in Heart Transplant Candidates

Author

Rushakoff, Joshua Adam, primary, Cao, Louie, additional, Ebinger, Joseph, additional, Kuo, Alexander, additional, Botting, Patrick G., additional, Emerson, Dominic, additional, Countance, Guillame, additional, Lebray, Pascal, additional, Tompkins, Rose, additional, Kobashigawa, Jon, additional, Patel, Jignesh K, additional, Guindi, Maha, additional, and Kransdorf, Evan, additional

Published
2023
Full Text
View/download PDF

21. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation

Author

Pageaux, Georges-Philippe, Duclos-Vallée, Jean-Charles, Coilly, Audrey, Bellissant, Eric, Botta-Fridlund, Danielle, Diallo, Alpha, Dumortier, Jérôme, Durand, François, Duvoux, Christophe, Fougerou-Leurent, Claire, Leroy, Vincent, Petrov-Sanchez, Ventzislava, Renault, Alain, Rohel, Alexandra, Roque, Anne-Marie, Taburet, Anne-Marie, Veislinger, Aurélie, Sebagh, Mylène, Radenne, Sylvie, Botta, Danielle, Silvain, Christine, Lebray, Pascal, Houssel-Debry, Pauline, Kamar, Nassim, D’Alteroche, Louis, and Duclos-Vallee, Jean-Charles

Published
2015
Full Text
View/download PDF

23. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases

Author

Grimaldi, André, Giral, Philippe, Bruckert, Eric, Basdevant, Arnaud, Clement, Karine, Oppert, Jean-Michel, Hartemann-Heurtier, Agnès, Andreelli, Fabrizio, Gombert, Sophie, Jacqueminet, Sophie, Cocaul, Arnaud, Fouffelle, Fabienne, Moussalli, Joseph, Thabut, Dominique, Lebray, Pascal, Podevin, Philippe, Bonnefont-Rousselot, Dominique, Bittar, Randa, Benhamou, Yves, Bernhardt, Carole, Boitard, Christian, Larger, Etienne, Sola, Agnès, El-Etr, Martine, Gautier, Jean-François, Serfaty, Lawrence, Housset, Chantal, Capeau, Jacqueline, Nascimbeni, Fabio, Fedchuk, Larysa, Oliveira, Claudia P., Alvares-da-Silva, Mario Reis, Varault, Anne, Ingiliz, Patrick, Ngo, Yen, de Torres, Mercedes, Munteanu, Mona, Poynard, Thierry, and Ratziu, Vlad

Published
2015
Full Text
View/download PDF

25. Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation

Author

Cortesi, Paolo Angelo, primary, Viganò, Raffaella, additional, Conti, Sara, additional, Lenci, Ilaria, additional, Volpes, Riccardo, additional, Martini, Silvia, additional, Angelico, Mario, additional, Fung, James, additional, Buti, Maria, additional, Coilly, Audrey, additional, Durand, Francois, additional, Fondevila, Constantino, additional, Lebray, Pascal, additional, Nevens, Frederik, additional, Polak, Wojciech G., additional, Rizzetto, Mario, additional, Zoulim, Fabien, additional, Perricone, Giovanni, additional, Berenguer, Marina, additional, Mantovani, Lorenzo Giovanni, additional, Duvoux, Christophe, additional, and Belli, Luca Saverio, additional

Published
2023
Full Text
View/download PDF

27. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Author

Meunier, Lucy, primary, Belkacemi, Mohamed, additional, Pageaux, George Philippe, additional, Radenne, Sylvie, additional, Vallet-Pichard, Anaïs, additional, Houssel-Debry, Pauline, additional, Duvoux, Christophe, additional, Botta-Fridlund, Danielle, additional, de Ledinghen, Victor, additional, Conti, Filomena, additional, Anty, Rodolphe, additional, Di Martino, Vincent, additional, Debette-Gratien, Marilyne, additional, Leroy, Vincent, additional, Gerster, Theophile, additional, Lebray, Pascal, additional, Alric, Laurent, additional, Abergel, Armand, additional, Dumortier, Jérôme, additional, Besch, Camille, additional, Montialoux, Helene, additional, Samuel, Didier, additional, Duclos-Vallée, Jean-Charles, additional, and Coilly, Audrey, additional

Published
2022
Full Text
View/download PDF

36. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

Author

Hézode, Christophe, Lebray, Pascal, De Ledinghen, Victor, Zoulim, Fabien, Di Martino, Vincent, Boyer, Nathalie, Larrey, Dominique, Botta‐Fridlund, Danielle, Silvain, Christine, Fontaine, Hélène, DʼAlteroche, Louis, Leroy, Vincent, Bourliere, Marc, Hubert‐Fouchard, Isabelle, Guyader, Dominique, Rosa, Isabelle, Nguyen‐Khac, Eric, Fedchuk, Larysa, Akremi, Raoudha, Bennai, Yacia, Filipovics, Anne, Zhao, Yue, and Bronowicki, Jean‐Pierre

Published
2017
Full Text
View/download PDF

37. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

Author

Duvoux, Christophe, Roudot–Thoraval, Françoise, Decaens, Thomas, Pessione, Fabienne, Badran, Hanaa, Piardi, Tullio, Francoz, Claire, Compagnon, Philippe, Vanlemmens, Claire, Dumortier, Jérome, Dharancy, Sébastien, Gugenheim, Jean, Bernard, Pierre–Henri, Adam, René, Radenne, Sylvie, Muscari, Fabrice, Conti, Filomena, Hardwigsen, Jean, Pageaux, Georges–Philippe, Chazouillères, Olivier, Salame, Ephrem, Hilleret, Marie–Noelle, Lebray, Pascal, Abergel, Armand, Debette–Gratien, Marilyne, Kluger, Michael D., Mallat, Ariane, Azoulay, Daniel, and Cherqui, Daniel

Published
2012
Full Text
View/download PDF

38. Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants

Author

Kamar, Nassim, Garrouste, Cyril, Haagsma, Elizabeth B., Garrigue, Valérie, Pischke, Sven, Chauvet, Cécile, Dumortier, Jérome, Cannesson, Amélie, Cassuto–Viguier, Elisabeth, Thervet, Eric, Conti, Filomena, Lebray, Pascal, Dalton, Harry R., Santella, Robert, Kanaan, Nada, Essig, Marie, Mousson, Christiane, Radenne, Sylvie, Roque–Afonso, Anne Marie, Izopet, Jacques, and Rostaing, Lionel

Published
2011
Full Text
View/download PDF

39. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study

Author

Henquell, Cécile, Guglielmini, Julien, Verbeeck, Jannick, Mahul, Antoine, Thibault, Vincent, Lebray, Pascal, Laperche, Syria, Trimoulet, Pascale, Foucher, Juliette, Le Guillou-Guillemette, Hélène, Fouchard-Hubert, Isabelle, Legrand-Abravanel, Florence, Métivier, Sophie, Gaudy, Catherine, D’Alteroche, Louis, Rosenberg, Arielle R., Podevin, Philippe, Plantier, Jean-Christophe, Riachi, Ghassan, Saoudin, Hénia, Coppere, Henri, André, Elisabeth, Gournay, Jérôme, Feray, Cyrille, Vallet, Sophie, Nousbaum, Jean-Baptiste, Baazia, Yazid, Roulot, Dominique, Alain, Sophie, Loustaud-Ratti, Véronique, Schvoerer, Evelyne, Habersetzer, François, Pérez-Serra, Rafael Juan, Gourari, Samir, Mirand, Audrey, Odent-Malaure, Hélène, Garraud, Olivier, Izopet, Jacques, Bommelaer, Gilles, Peigue-Lafeuille, Hélène, van Ranst, Marc, Abergel, Armand, and Bailly, Jean-Luc

Published
2011
Full Text
View/download PDF

42. Diagnosis and management of hepatic encephalopathy: The French recommendations.

Author

Thabut, Dominique, Bouzbib, Charlotte, Meunier, Lucy, Haas, Manon, Weiss, Nicolas, Louvet, Alexandre, Imbert‐Bismut, Francois, Mochel, Fanny, Nadjar, Yann, Santiago, Antoine, Thevenot, Thierry, Duhalde, Véronique, Oberti, Frédéric, Francoz, Claire, Coilly, Audrey, Hilleret, Marie‐Noelle, Lebray, Pascal, Liou‐Schischmanoff, Amélie, Barbier, Louise, and Duvoux, Christophe

Subjects
HEPATIC encephalopathy, PATIENT selection, DIAGNOSIS, LIVER transplantation, NEUROLOGICAL disorders
Abstract

Hepatic encephalopathy (HE) is a frequent and severe complication of liver disease with poor patient outcomes. However, it is a poorly understood complication, with no consensus for diagnosis. Therefore, HE is often underdiagnosed. Differential diagnosis may be cumbersome because of non‐specific symptoms, such as confusion, cognitive disorders, the aetiological factors of cirrhosis and comorbidities, which are often observed in cirrhotic patients. Therefore, an overt or covert form of HE should be systematically investigated. Advice is provided to drive patient work‐up. Effective treatments are available to prevent or treat HE bouts, but the issue of single or combination therapy has not been resolved. Transjugular intrahepatic portosystemic shunt (TIPS) placement largely improved the prognosis of cirrhotic patients, but HE occurrence of HE is often a fear, even when post‐TIPS HE can be avoided by a careful selection of patients and preventive treatment. HE is an indication of liver transplantation. However, its reversibility post‐transplantation and the consequences of transplantation in patients with other causes of neurological disorders remain controversial, which supports the performance of an extensive work‐up in expert centres for this subset of patients. The present guidelines assist clinicians in the diagnosis of the overt or covert form of HE to implement curative and preventive treatments and clarify which patients require referral to expert centres for consideration for liver transplantation. These guidelines are very clinically oriented and address different frequent clinical issues to help physicians make bedside decisions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Author

Meunier, Lucy, Belkacemi, Mohamed, Pageaux, George Philippe, Radenne, Sylvie, Vallet-Pichard, Anaïs, Houssel-Debry, Pauline, Duvoux, Christophe, Botta-Fridlund, Danielle, de Ledinghen, Victor, Conti, Filomena, Anty, Rodolphe, Di Martino, Vincent, Debette-Gratien, Marilyne, Leroy, Vincent, Gerster, Theophile, Lebray, Pascal, Alric, Laurent, Abergel, Armand, Dumortier, Jérôme, and Besch, Camille

Subjects
LIVER transplantation, HEPATITIS C virus, HEPATOCELLULAR carcinoma, DEEP brain stimulation, BRAIN stimulation, PATIENT safety
Abstract

Background: Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the long term, data remain minimal regarding the clinical impact of viral eradication on patients listed for decompensated cirrhosis or hepatocellular carcinoma (HCC). We aimed to elucidate the clinical outcomes of patients regarding delisting and the evolution of HCC during the long-term follow-up. Methods: An observational, multicenter, retrospective analysis was carried out on prospectively collected data from HCV-positive patients treated with an interferon-free regimen while awaiting LT in 18 French hospitals. Results: A total of 179 patients were included in the study. The indication for LT was HCC in 104 (58.1%) patients and cirrhosis in 75 (41.9%) patients. The sustained virological response was 84.4% and the treatment was well tolerated. At five years, among 75 patients with cirrhosis treated for HCV, 19 (25.3%) were delisted following improvement after treatment. Predictive factors for delisting highlighted an absence of ascites, MELD score ≤ 15, and Child–Pugh score ≤ 7. No patients with refractory ascites were delisted. Among patients with HCC, 82 (78.9%) were transplanted. The drop-out rate was low (6.7%) and few recurrences of HCC after LT were observed. Conclusions: DAAs are safe and effective in patients awaiting LT for cirrhosis or HCC. A quarter of patients with cirrhosis can be delisted because of clinical improvement. Predictive factors for delisting, as a result of improvement, may assist prescribers, before initiating HCV infection therapy in the long-term perspective. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: The ANRS CO23 CUPILT study: 21

Author

Leroy, Vincent, Dumortier, Jérôme, Coilly, Audrey, Sebagh, Mylene, Fougerou-Leurent, Claire, Radenne, Sylvie, Botta, Danielle, Durand, Francois, Silvain, Christine, Lebray, Pascal, Houssel-Debry, Pauline, Kamar, Nassim, dʼAlteroche, Louis, Calmus, Yvon, Bertucci, Inga, Pageaux, Georges-Philippe, and Duclos-Vallee, Jean-Charles

Published
2014

48. Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

Author

Kamar, Nassim, Izopet, Jacques, Tripon, Simona, Bismuth, Michael, Hillaire, Sophie, Dumortier, Jérôme, Radenne, Sylvie, Coilly, Audrey, Garrigue, Valérie, DʼAlteroche, Louis, Buchler, Matthias, Couzi, Lionel, Lebray, Pascal, Dharancy, Sebastien, Minello, Anne, Hourmant, Maryvonne, Roque-Afonso, Anne-Marie, Abravanel, Florence, Pol, Stanislas, Rostaing, Lionel, and Mallet, Vincent

Published
2014
Full Text
View/download PDF

49. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplantation

Author

Duvoux, Christophe, primary, Belli, Luca S., additional, Fung, James, additional, Angelico, Mario, additional, Buti, Maria, additional, Coilly, Audrey, additional, Cortesi, Paolo, additional, Durand, François, additional, Féray, Cyrille, additional, Fondevila, Constantino, additional, Lebray, Pascal, additional, Martini, Silvia, additional, Nevens, Frederik, additional, Polak, Wojciech G., additional, Rizzetto, Mario, additional, Volpes, Riccardo, additional, Zoulim, Fabien, additional, Samuel, Didier, additional, and Berenguer, Marina, additional

Published
2021
Full Text
View/download PDF

50. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation

Author

Kamar, Nassim, Legrand-Abravanel, Florence, Behrendt, Patrick, Hofmann, Jörg, Pageaux, Georges Phillippe, Barbet, Christelle, Moal, Valerie, Couzi, Lionel, Horvatits, Thomas, de Man, Robert, Cassuto, Elisabeth, Elsharkawy, Ahmed, Riezebos-Brilman, Annelies, Scemla, Anne, Hillaire, Sophie, Donnelly, Mhairi, Radenne, Sylvie, Sayegh, Johnny, Garrouste, Cyril, Dumortier, Jérôme, Glowaki, François, Matignon, Marie, Coilly, Audrey, Figueres, Lucile, Mousson, Christiane, Minello, Anne, Dharancy, Sébastien, Rerolle, Jean Philippe, Lebray, Pascal, Etienne, Isabelle, Perrin, Peggy, Choi, Mira, Olivier, Marion, Izopet, Jacques, Bellière, J, Cointault, O., del Bello, Arnaud, Espostio, L, Hebral, A, Lavayssière, L, Lhomme, S, Mansuy, J, Wedemeyer, H, Nickel, P, Bismuth, M., Stefic, K, Buchler, M., D’alteroche, L, Colson, P., Bufton, S, Ramière, C, Trimoulet, P., Pischke, S, Todesco, E, Sberro Soussan, R, Legendre, C, Mallet, V., Johannessen, I, Simpson, K, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées, Hannover Medical School [Hannover] (MHH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), CHU Bordeaux [Bordeaux], Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre Hospitalier Universitaire de Nice (CHU Nice), University Hospitals Birmingham [Birmingham, Royaume-Uni], University Medical Center Groningen [Groningen] (UMCG), Réseau CENTAURE, Hôpital Foch [Suresnes], Royal Infirmary of Edinburgh, Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Clermont-Ferrand, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Paul Brousse, Centre hospitalier universitaire de Nantes (CHU Nantes), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Hôpital Claude Huriez [Lille], CHU Lille, Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Rouen, Normandie Université (NU), CHU Strasbourg, Département de Néphrologie et Transplantation d'organes [Toulouse], Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Gastroenterology & Hepatology, CHU Toulouse [Toulouse]-Hôpital de Rangueil, Université de Montpellier (UM)-CHU Saint-Eloi, Service de néphrologie et immunologie clinique [CHRU Tours] (EA4245 UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours, Département de Néphrologie et Transplantation d'organes, Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service de néphrologie et immunologie clinique, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
0301 basic medicine, MESH: Antiviral Agents / therapeutic use, Sofosbuvir, viruses, medicine.disease_cause, Gastroenterology, THERAPY, Organ transplantation, Hepatitis E virus / genetics, Hepatitis E / drug therapy, Humans, chemistry.chemical_compound, 0302 clinical medicine, Hepatitis E virus, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, MUTATION, MESH: Hepatitis E* / drug therapy, POLYMERASE, organ transplantation, virus diseases, MESH: Ribavirin / therapeutic use, Anemia, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Hepatitis E, anemia, 3. Good health, PREDICTS, Sustained virological response, Infectious Diseases, MESH: RNA, Viral, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, 030211 gastroenterology & hepatology, sustained virological response, medicine.drug, Microbiology (medical), medicine.medical_specialty, ribavirin, MESH: Organ Transplantation / adverse effects, RNA, Viral Retrospective Studies, Ribavirin / therapeutic use, Alpha interferon, MESH: Organ Transplantation* / adverse effects, hepatitis E virus, Antiviral Agents, Virus, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Ribavirin, Retrospective Studies, MESH: Hepatitis E virus* / genetics, MESH: Humans, business.industry, Retrospective cohort study, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, IN-VITRO, medicine.disease, digestive system diseases, 030104 developmental biology, chemistry, SOFOSBUVIR, HEV, REPLICATION, INTERFERON-ALPHA, business
Abstract

Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance. This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results